Advances in novel therapies for children with Hodgkin lymphoma
10.3760/cma.j.issn.1673-4408.2025.10.006
- VernacularTitle:儿童霍奇金淋巴瘤治疗新方法研究进展
- Author:
Xinyu QIAO
1
;
Yijin GAO
Author Information
1. 上海交通大学医学院附属上海儿童医学中心肿瘤科 200127
- Keywords:
Children;
Hodgkin lymphoma;
Brentuximab vedotin;
Immune checkpoint inhibitors;
Immune cell therapy
- From:
International Journal of Pediatrics
2025;52(10):676-680
- CountryChina
- Language:Chinese
-
Abstract:
Hodgkin lymphoma（HL）is one of the common pediatric malignancies（especially in adolescents）. The prognosis of pediatric patients with HL is excellent with traditional first-line treatment regimens involving short-course，high-dose combination chemotherapy and low-intensity radiotherapy，resulting in an overall response rate of 90%. However，10%-25% of pediatric HL patients are estimated to have relapsed/refractory（r/r）disease，and survivors of pediatric HL are at risk of late effects caused by traditional treatment regimens. For children with r/r HL，novel therapies，such as brentuximab vedotin，immune checkpoint inhibitors and immune cell therapy，including chimeric antigen receptor T-cell therapy and EBV-specific cytotoxic T lymphocytes are an integral part of their salvage treatment and consolidation treatment after hematopoietic stem cell transplantation. Furthermore，combining novel therapies with first-line treatment regimens for pediatric HL may help enhance therapeutic efficacy and reduce treatment toxicity. This review is aimed to describe current advances in novel therapies for pediatric HL，and serve as a reference for clinical practice.
